TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7818588

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 2.2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 4.4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 8.8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 17.6 mg
Number of subjects: 12
Study: 3061353

Group type: EXPERIMENTAL
Intervention: Simple excision of anal papillae
Number of subjects: 41

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 41
Study: 30110579

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg once daily)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Standard therapy (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 431

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 431
Study: 26671747

Group type: EXPERIMENTAL
Intervention: H. pylori eradication (n=19)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Non-eradicated patients (n=17)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 131
Study: 25714598

Group type: EXPERIMENTAL
Intervention: Inclacumab (0.03-20 mg/kg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inclacumab
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24328444

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2584

Group type: COMPARATOR
Intervention: Control (hepatitis A vaccine)
Number of subjects: 2584
Study: 21349483

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mEq/L, 0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sodium chloride (0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Number of subjects: 59
Study: 18753003

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (0.5-4mg/24h)
Number of subjects: 295
Study: 12419727

Group type: EXPERIMENTAL
Intervention: Dopamine (4 and 8 microgram*kg(‐1)*min(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dobutamine (4 and 8 microgram*kg(‐1)*min(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of dopamine and dobutamine at 8 microgram*kg(‐1)*min(‐1)
Number of subjects: 14
Study: 9602596

Group type: EXPERIMENTAL
Intervention: Droperidol 25 micrograms kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120
Study: 7648115

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 168

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 168
Study: 2667745

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no tamoxifen therapy)
Number of subjects: 100
Study: 318578

Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG)
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 2204
Study: 31074827

Group type: EXPERIMENTAL
Intervention: Mother's milk alone (MM)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Hybrid feed (HF)
Number of subjects: 112
Study: 31282592

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg on days 2-7) with Itacitinib (200 mg on days 1 and 6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg on days 2-9) with Itacitinib (200 mg on days 1 and 9)
Number of subjects: 36
Study: 27997965

Group type: EXPERIMENTAL
Intervention: 12-month reminder plus standard information booklet (TMR-SIB)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: 12-month reminder plus bespoke theory-based leaflet (TMR-TBL)
Number of subjects: 1383

Group type: COMPARATOR
Intervention: No reminder (control)
Number of subjects: 1383
Study: 25915712

Group type: EXPERIMENTAL
Intervention: BRIA psychotherapy sessions up to 3 months postoperatively
Number of subjects: 220

Group type: COMPARATOR
Intervention: No psychotherapy/computerized brief written advice (BWA)
Number of subjects: 220
Study: 23487278

Group type: EXPERIMENTAL
Intervention: Family group intervention at CPAA centers (Group B)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard program for patients and relatives (Group A)
Number of subjects: 188
Study: 21831711

Group type: EXPERIMENTAL
Intervention: Immediate pre-TURBT EMDA mitomycin (40 mg in 100 mL sterile water with 20 mA pulsed electric current for 30 min)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Immediate pre-TURBT EMDA mitomycin
Number of subjects: 374

Group type: COMPARATOR
Intervention: TURBT alone
Number of subjects: 374

Group type: COMPARATOR
Intervention: Immediate post-TURBT PD mitomycin
Number of subjects: 374
Study: 19350369

Group type: EXPERIMENTAL
Intervention: Manualized behavioral treatment including motivational interviewing and cognitive therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 14
Study: 16622140

Group type: EXPERIMENTAL
Intervention: Amalgam restorations for posterior lesions (n = 253)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Resin composite restorations instead of amalgam (n = 254)
Number of subjects: 507
Study: 14977161

Group type: EXPERIMENTAL
Intervention: Inhaler
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 4 mg gum
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 mg gum
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 mg tablet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nasal spray
Number of subjects: 41
Study: 11430618

Group type: EXPERIMENTAL
Intervention: +/-0.50 D spherical binocular and monocular errors
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reference pair of spectacles
Number of subjects: 15
Study: 9244228

Group type: EXPERIMENTAL
Intervention: Midodrine (5 to 10 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: I.V. saline (1 L)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg)
Number of subjects: 13
Study: 7957496

Group type: EXPERIMENTAL
Intervention: 63 h of sleeplessness (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vertical sleep in a seated position for three consecutive nights (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls (group C)
Number of subjects: 40
Study: 30056321

Group type: EXPERIMENTAL
Intervention: Educational intervention (interactive HIV flipbook and HCV video)
Number of subjects: 25
Study: 27165542

Group type: EXPERIMENTAL
Intervention: Acetylic Salicylic Acid (ASA) 500 mg once daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24840857

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g day(‐1) for 7 days followed by 5 g day(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PL-dextrose)
Number of subjects: 32
Study: 22342927

Group type: EXPERIMENTAL
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 55
Study: 19335940

Group type: EXPERIMENTAL
Intervention: Stainless steel cooking pots distributed to households in Nduta camp (intervention)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Aluminium or clay pots used in households in Mtendeli camp (control)
Number of subjects: 220
Study: 18608735

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream plus NB-UVB
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo plus NB-UVB
Number of subjects: 68
Study: 16797280

Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Hook F. (T II)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (no T II)
Number of subjects: 223
Study: 14572747

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg in addition to standard care
Number of subjects: 0
Study: 10701823

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Enalapril (10 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9234049

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg/70 kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg/70 kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 6
Study: 8148031

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement (Phosphacap)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (Ketac-Cem Maxicap)
Number of subjects: 12
Study: 3527692

Group type: EXPERIMENTAL
Intervention: Sensory information about the exam
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Training in coping skills (deep breathing and positive self‐talk)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined sensory information and coping skills training
Number of subjects: 79

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 79

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 79
Study: 29910052

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD) patients
Number of subjects: 4098

Group type: EXPERIMENTAL
Intervention: First nonfatal ischemic event in PAD patients
Number of subjects: 4098
Study: 26980847

Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cloth masks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerosol-generating procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact with febrile respiratory illness patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance with medical or cloth masks (average use ≥70% of working time)
Number of subjects: 0
Study: 24139558

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (2.5mg/kg every 12 hours for 48 hours intravenously)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (isotonic saline 1.25 ml/kg/doses intravenously every 12 hours for 48 hours)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 50
Study: 22337227

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (1.1 g/d n-3 LCPUFA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no fish oil)
Number of subjects: 78
Study: 20410410

Group type: EXPERIMENTAL
Intervention: Low-dose ungated MDCT
Number of subjects: 584
Study: 18580613

Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 63
Study: 15955616

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) + 2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 30
Study: 12217947

Group type: EXPERIMENTAL
Intervention: Baclofen (15 mg/day for the first 3 days, then 30 mg/day for 27 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 10028213

Group type: EXPERIMENTAL
Intervention: Mixed-syndrome children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall tendencies
Number of subjects: 0
Study: 8607000

Group type: EXPERIMENTAL
Intervention: Chronic CPAP therapy (Continuous Positive Airway Pressure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normocapnic OSA and overlap group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic hypercapnic OSA
Number of subjects: 0
Study: 2385125

Group type: EXPERIMENTAL
Intervention: Reinfusion of autologous platelet-rich plasma
Number of subjects: 18

Group type: COMPARATOR
Intervention: No reinfusion of platelet-rich plasma (control group)
Number of subjects: 18
Study: 7386493

Group type: EXPERIMENTAL
Intervention: Thyroid hormone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 20
Study: 31704188

Group type: EXPERIMENTAL
Intervention: Oral calcitriol at 0.25 μg, 3 times weekly with ACEI or ARB
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACEI or ARB (control group)
Number of subjects: 60
Study: 30945478

Group type: EXPERIMENTAL
Intervention: High Concentration Oxygen Therapy (HCOT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Titrated Oxygen Therapy (TOT)
Number of subjects: 96
Study: 27020489

Group type: EXPERIMENTAL
Intervention: 200 μg sublingual misoprostol with cervical laminaria
Number of subjects: 70

Group type: COMPARATOR
Intervention: 400 μg sublingual misoprostol without laminaria
Number of subjects: 70
Study: 25821725

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10% KOH solution
Number of subjects: 40
Study: 23594463

Group type: EXPERIMENTAL
Intervention: Penicillin V 1.6 million units thrice-daily for 10 days
Number of subjects: 210

Group type: COMPARATOR
Intervention: Amoxicillin 1,000 mg thrice-daily for 10 days
Number of subjects: 210
Study: 21386066

Group type: EXPERIMENTAL
Intervention: 60‐second video training (n=95)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: 5‐minute video training (n=99)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: 8‐minute video training, including manikin practice (n=91)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: All experimental groups
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (n=51)
Number of subjects: 336
Study: 19561521

Group type: EXPERIMENTAL
Intervention: Structured isotonic strength training (ST) program, 24 sessions (3 per week for 8 weeks).
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 16
Study: 17666194

Group type: EXPERIMENTAL
Intervention: Telmisartan (an ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with telmisartan and ramipril (an ACE inhibitor)
Number of subjects: 0
Study: 14629234

Group type: EXPERIMENTAL
Intervention: Patient-centred guidebook
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no guidebook)
Number of subjects: 240
Study: 11084548

Group type: EXPERIMENTAL
Intervention: High-dose intravaginal misoprostol (600 microg vaginally)
Number of subjects: 9
Study: 9487348

Group type: EXPERIMENTAL
Intervention: Colistin (2 MU tds intravenously) alone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Colistin (2 MU tds intravenously) with a second anti-pseudomonal antibiotic (dual therapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study: 8368227

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pamidronate (all doses)
Number of subjects: 50
Study: 3521761

Group type: EXPERIMENTAL
Intervention: Methotrexate and cyclosporine (n = 22)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Methotrexate alone (n = 24)
Number of subjects: 46
Study: 31732742

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 30693611

Group type: EXPERIMENTAL
Intervention: Project-based treatment (20 hours over 6 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 21
Study: 28800382

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis (200 mg of SMX/40 mg of TMP once daily)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Regimens of 30 mg kg-1 of SMX and 6 mg kg-1 of TMP for the 5-10 kg group and 25 mg kg-1 of SMX and 5 mg kg-1 of TMP for the 10-15 kg group
Number of subjects: 136
Study: 25887433

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation program (12 weeks of physical exercise and psycho-educational intervention with five consultations)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study: 23969513

Group type: EXPERIMENTAL
Intervention: Pertuzumab combined with trastuzumab and docetaxel
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 37

Group type: COMPARATOR
Intervention: Trastuzumab and docetaxel
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel combination
Number of subjects: 37
Study: 21855741

Group type: EXPERIMENTAL
Intervention: Maintenance Counseling group (n=64)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Contact Control group (n=66)
Number of subjects: 130
Study: 19891902

Group type: EXPERIMENTAL
Intervention: Cervical cytology plus HPV testing (revealed arm)
Number of subjects: 24510

Group type: COMPARATOR
Intervention: Cervical cytology (concealed arm)
Number of subjects: 24510
Study: 17805238

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-phosphorus diet alone
Number of subjects: 90
Study: 15541448

Group type: EXPERIMENTAL
Intervention: bivalent HPV-16/18 L1 virus-like particle vaccine
Number of subjects: 1113

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1113
Study: 11922382

Group type: EXPERIMENTAL
Intervention: Intensive screening programme with regular visual assessments by orthoptists (testing visual acuity, ocular alignment, stereopsis, and non-cycloplegic photorefraction)
Number of subjects: 3689

Group type: COMPARATOR
Intervention: Visual surveillance only (control group)
Number of subjects: 3689

Group type: EXPERIMENTAL
Intervention: Photorefraction
Number of subjects: 3689

Group type: EXPERIMENTAL
Intervention: Visual acuity testing plus cover test
Number of subjects: 3689
Study: 9734613

Group type: EXPERIMENTAL
Intervention: Diltiazem CD
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 21
Study: 8034784

Group type: EXPERIMENTAL
Intervention: SofScale calculus scaling gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2659679

Group type: EXPERIMENTAL
Intervention: Combination of heat‐killed Leishmania mexicana amazonensis promastigotes and viable BCG
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate chemotherapy
Number of subjects: 217

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Combined immunotherapy
Number of subjects: 217
Study: 31711041

Group type: EXPERIMENTAL
Intervention: Mézières method postural therapy (60 minutes, 2-3 sessions per week for 24 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mézières method postural therapy
Number of subjects: 90
Study: 29855308

Group type: EXPERIMENTAL
Intervention: 8 weeks of aerobic exercise, 3 times a week, 20 minutes per session
Number of subjects: 65
Study: 28263203

Group type: EXPERIMENTAL
Intervention: Systolic OHT at 3 minutes after standing
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Orthostatic hypotension (OH)
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Orthostatic hypertension (OHT)
Number of subjects: 1176
Study: 25535985

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg weekly (group A, 159 patients)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Etanercept 25 mg bi-weekly (group B, 164 patients)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg weekly (group A)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Etanercept half-dose regimen
Number of subjects: 524
Study: 23844093

Group type: EXPERIMENTAL
Intervention: 100%CAPS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 75%CAPS
Number of subjects: 4

Group type: COMPARATOR
Intervention: 75%Control
Number of subjects: 4

Group type: COMPARATOR
Intervention: 100%Control
Number of subjects: 4
Study: 21696359

Group type: EXPERIMENTAL
Intervention: Dark chocolate intake (mild: 1-2 bars/week, moderate: 3-4 bars/week, high: > 4 bars/week)
Number of subjects: 14310

Group type: EXPERIMENTAL
Intervention: Dark chocolate intake
Number of subjects: 14310

Group type: EXPERIMENTAL
Intervention: Higher dark chocolate intake
Number of subjects: 14310
Study: 19835299

Group type: EXPERIMENTAL
Intervention: Ultrasound-based navigation
Number of subjects: 25
Study: 16882265

Group type: COMPARATOR
Intervention: Closure of both the visceral and parietal peritoneum (C-group, n = 70)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Non-closure of the peritoneum (NC-group, n = 54)
Number of subjects: 124
Study: 14988134

Group type: EXPERIMENTAL
Intervention: Computer prompts from the R2 ImageChecker 1000
Number of subjects: 50

Group type: COMPARATOR
Intervention: No prompts (unprompted condition)
Number of subjects: 50
Study: 11248713

Group type: EXPERIMENTAL
Intervention: Women with heart failure
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Men with heart failure
Number of subjects: 1382
Study: 9037216

Group type: EXPERIMENTAL
Intervention: White, Hispanic, and Asian students
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: White and Hispanic students
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: White and Asian students
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: White student
Number of subjects: 83

Group type: COMPARATOR
Intervention: Black student
Number of subjects: 83
Study: 7633085

Group type: EXPERIMENTAL
Intervention: Use of thermal drape during anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: No thermal drape during anaesthesia
Number of subjects: 0
Study: 3388405

Group type: EXPERIMENTAL
Intervention: 50% Hartmann's + 50% 5% Dextrose (HD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 100% Hartmann's (H)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 100% Plasmalyte 148 (P)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CPD stored blood
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate buffer
Number of subjects: 29
Study: 31135225

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement (109 CFU/day) for 10 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88